Sandy Griffith

2.5k total citations
17 papers, 507 citations indexed

About

Sandy Griffith is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, Sandy Griffith has authored 17 papers receiving a total of 507 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Infectious Diseases, 12 papers in Virology and 3 papers in Epidemiology. Recurrent topics in Sandy Griffith's work include HIV/AIDS drug development and treatment (14 papers), HIV Research and Treatment (12 papers) and HIV/AIDS Research and Interventions (11 papers). Sandy Griffith is often cited by papers focused on HIV/AIDS drug development and treatment (14 papers), HIV Research and Treatment (12 papers) and HIV/AIDS Research and Interventions (11 papers). Sandy Griffith collaborates with scholars based in United States, Belgium and Canada. Sandy Griffith's co-authors include William Spreen, Krischan J Hudson, Susan L. Ford, Kimberly Y. Smith, Joseph J. Eron, Britt Stancil, Peter Williams, M H St Clair, Jerome De Vente and Cynthia Brinson and has published in prestigious journals such as SHILAP Revista de lepidopterología, The Lancet Infectious Diseases and British Journal of Clinical Pharmacology.

In The Last Decade

Sandy Griffith

17 papers receiving 494 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sandy Griffith United States	10	442	322	115	78	31	17	507
Linda Akagi Canada	5	290 0.7×	178 0.6×	84 0.7×	103 1.3×	21 0.7×	8	419
Miguel Goicoechea United States	10	467 1.1×	282 0.9×	129 1.1×	183 2.3×	39 1.3×	24	572
Christopher Stone United States	10	672 1.5×	550 1.7×	147 1.3×	108 1.4×	20 0.6×	18	733
Sharon M. Seifert United States	11	476 1.1×	242 0.8×	209 1.8×	80 1.0×	21 0.7×	15	538
Mark Becker United States	9	453 1.0×	399 1.2×	53 0.5×	87 1.1×	21 0.7×	10	520
Kati Vandermeulen Belgium	12	651 1.5×	480 1.5×	133 1.2×	177 2.3×	54 1.7×	19	713
Arturo Ciccullo Italy	13	430 1.0×	307 1.0×	126 1.1×	148 1.9×	15 0.5×	70	510
Ashwaq Hermes United States	7	277 0.6×	174 0.5×	58 0.5×	80 1.0×	39 1.3×	8	359
Rodica Van Solingen‐Ristea United States	11	296 0.7×	187 0.6×	119 1.0×	38 0.5×	34 1.1×	31	375
Janet Nicotera United States	8	389 0.9×	266 0.8×	182 1.6×	84 1.1×	51 1.6×	12	515

Countries citing papers authored by Sandy Griffith

Since Specialization

Citations

This map shows the geographic impact of Sandy Griffith's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sandy Griffith with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sandy Griffith more than expected).

Fields of papers citing papers by Sandy Griffith

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sandy Griffith. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sandy Griffith. The network helps show where Sandy Griffith may publish in the future.

Co-authorship network of co-authors of Sandy Griffith

This figure shows the co-authorship network connecting the top 25 collaborators of Sandy Griffith. A scholar is included among the top collaborators of Sandy Griffith based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sandy Griffith. Sandy Griffith is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Czarnogorski, Maggie, Paul Benn, Sandy Griffith, et al.. (2022). Brief Report: Impact of COVID-19 on Cabotegravir Plus Rilpivirine Long-Acting Dosing Across 6 Ongoing Global Phase IIb and III Clinical Trials. JAIDS Journal of Acquired Immune Deficiency Syndromes. 91(2). 157–161. 2 indexed citations

Mahvash, Armeen, Suzanne Chartier, Marco Rosselli Del Turco, et al.. (2021). A prospective, multicenter, open-label, clinical trial design to evaluate the safety and efficacy of 90Y resin microspheres for treatment of unresectable hepatocellular carcinoma (HCC): DOORwaY90. HPB. 23. S545–S546. 1 indexed citations

Orkin, Chloe, Enrique Bernal, Darrell H. S. Tan, et al.. (2021). Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study. The Lancet HIV. 8(11). e668–e678. 88 indexed citations

Mantsios, Andrea, Miranda Murray, Tahilin Sanchez Karver, et al.. (2020). Efficacy and Freedom: Patient Experiences with the Transition from Daily Oral to Long-Acting Injectable Antiretroviral Therapy to Treat HIV in the Context of Phase 3 Trials. AIDS and Behavior. 24(12). 3473–3481. 35 indexed citations

Wu, Sterling, Feifan Zhang, David Dorey, et al.. (2020). 1029. Long-Term Patient Adherence and Management of Treatment Interruptions With Long-Acting Injectable Cabotegravir + Rilpivirine for Maintenance Therapy in Phase IIb/III Studies. Open Forum Infectious Diseases. 7(Supplement_1). S544–S544. 2 indexed citations

Murray, Miranda, Antonio Antela, Anthony Mills, et al.. (2020). Patient-Reported Outcomes in ATLAS and FLAIR Participants on Long-Acting Regimens of Cabotegravir and Rilpivirine Over 48 Weeks. AIDS and Behavior. 24(12). 3533–3544. 53 indexed citations

Talarico, Christine L., Sterling Wu, Marty St. Clair, et al.. (2020). 1021. HIV-1 RNA Blips and Low-Level Replication During Phase III/IIIb Cabotegravir + Rilpivirine Long-Acting Studies Are Similar to Oral 3-Drug Therapy and Not Associated with Week 48 Virologic Outcome. Open Forum Infectious Diseases. 7(Supplement_1). S540–S541. 4 indexed citations

D’Amico, Ronald, Paul Benn, Cynthia McCoig, et al.. (2020). LB-8. Summary of COVID-Related Impact on Cabotegravir and Rilpivirine Long-Acting (CAB+RPV LA) Dosing Across the Six Ongoing Global Phase IIb and IIIb Clinical Trials. Open Forum Infectious Diseases. 7(Supplement_1). S847–S848. 2 indexed citations

Chounta, Vasiliki, Enrique Bernal, Johan Lombaard, et al.. (2020). 1035. Patient-Reported Outcomes on Long-Acting Cabotegravir + Rilpivirine as Maintenance Therapy: FLAIR 96-Week Results. Open Forum Infectious Diseases. 7(Supplement_1). S548–S548. 4 indexed citations

10.

Patel, Parul, Susan L. Ford, Herta Crauwels, et al.. (2019). 2495. Pharmacokinetics of Cabotegravir (CAB) and Rilpivirine (RPV) Long-Acting (LA) Injectables in HIV-infected Individuals through 48 Weeks in the FLAIR and ATLAS Phase 3 Studies. Open Forum Infectious Diseases. 6(Supplement_2). S865–S866. 17 indexed citations

11.

Cutrell, Amy, Ronald D’Amico, David Dorey, et al.. (2019). 884. Patient Adherence to Long-Acting Injectable Cabotegravir + Rilpivirine Through 48 Weeks of Maintenance Therapy in the Phase 3 ATLAS and FLAIR Studies. Open Forum Infectious Diseases. 6(Supplement_2). S20–S20. 4 indexed citations

12.

Murray, Miranda, Federico Pulido, Anthony Mills, et al.. (2019). Patient-reported tolerability and acceptability of cabotegravir + rilpivirine long-acting injections for the treatment of HIV-1 infection: 96-week results from the randomized LATTE-2 study. SHILAP Revista de lepidopterología. 20(4-5). 111–122. 26 indexed citations

13.

Margolis, David A., Cynthia Brinson, Graham Smith, et al.. (2015). Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial. The Lancet Infectious Diseases. 15(10). 1145–1155. 157 indexed citations

14.

Cahn, Pedro, Jaime Andrade‐Villanueva, Carlos Beltrán, et al.. (2015). P032: Dolutegravir versus raltegravir in ARV-experienced INI-naïve HIV+ adults: 48-week subgroup analysis of Latin American subjects in the SAILING study. Journal of the International AIDS Society. 18(3 (Suppl 2)). 9 indexed citations

15.

Miller, Ann K., Ye Li, Jőrg‐Peter Kleim, et al.. (2013). Pharmacokinetic interactions and safety evaluations of coadministered tafenoquine and chloroquine in healthy subjects. British Journal of Clinical Pharmacology. 76(6). 858–867. 36 indexed citations

16.

Bartlett, John, Judy Johnson, Néstor Sosa, et al.. (2006). Long-Term Results of Initial Therapy With Abacavir and Lamivudine Combined With Efavirenz, Amprenavir/Ritonavir, or Stavudine. JAIDS Journal of Acquired Immune Deficiency Syndromes. 43(3). 284–292. 56 indexed citations

17.

Nadler, Jeffrey P., Joseph Gathe, Richard B. Pollard, et al.. (2003). Twice-daily amprenavir 1200 mg versus amprenavir 600 mg/ritonavir 100 mg, in combination with at least 2 other antiretroviral drugs, in HIV-1-infected patients. BMC Infectious Diseases. 3(1). 10–10. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact